BenfoTeam Study
The BenfoTeam Study tests if increasing thiamine in the blood slows cognitive decline in people with early Alzheimer’s disease, including Mild Cognitive Impairment (MCI) and mild dementia.
VR Study
Virtual Reality Brain Health Study is a novel study that uses three methods of lifestyle intervention involving physical exercise and Virtual Reality to promote brain health and cognition in older adults which takes place in San Diego, California.
VIVA-MIND Study
The VIVA-MIND trial is designed to determine if the study drug, varoglutamstat, can stabilize or slow memory and thinking problems that increase in early AD.
3 Star Study
The 3 Star Study will research and test whether an investigational vaccine can affect Alzheimer’s disease-related brain changes in participants with Down Syndrome.The 3 Star Study is designed for individuals who have Down Syndrome, are 25-45 years of age, do not have any other serious illness, and have a caregiver or informant who can answer questions about them.
UC Cures SALAD Study
SALAD is a Phase 1b, 12-month, randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of salsalate in patients with mild to moderate Alzheimer’s disease.
DISCOVER Study
The Discover Study is a randomized, double-blind, placebo controlled study. Participants will be treated with a low, middle, or high dose of Posiphen, or a placebo (a capsule that looks like the study drug but does not contain active ingredients).
PEACE-AD Study
PEACE-AD is a multicenter, randomized, placebo-controlled study evaluating the efficacy and safety of the Prazosin drug.
UC Cures NEAT Study
NEAT is a Phase 2, proof of concept, double-blind, randomized, placebo-controlled adaptive design trial of Nicotinamide in MCI due to AD and Mild AD Dementia.
NOBLE Study
NOBLE is a clinical study to evaluate an investigational drug for patients with mild to moderate Alzheimer’s disease. The investigational drug may work by protecting brain cells, which could result in improved memory. The study will determine whether the drug is efficacious.
Resveratrol Study
A Phase II clinical study of Resveratrol (RES) designed to evaluate the safety, tolerability and effectiveness of Resveratrol on cerebrospinal fluid and other biomarkers for the treatment of Alzheimer’s disease.
Home-Based Assessments Study
Evaluate three methods of performing home-based assessments in an Alzheimer’s disease prevention trial.
Nerve Growth Factor Study
Ceregene’s CERE-110 gene therapy product designed to deliver nerve growth factor (NGF) to the brain for the treatment of Alzheimer’s disease is currently underway.
ADNI Study
Determine whether imaging of the brain every six months can help predict the onset of Alzheimer’s disease, and monitor the progression of the disease as well.
GAP Study
Further examination of the safety, effectiveness and tolerability of IVIg in mild to moderate Alzheimer’s Disease patients.
Docosahexaenoic Acid Study
A randomized, double-blind, placebo-controlled trial of the effects of Docosahexaenoic Acid (DHA) in slowing the progression of Alzheimer’s disease.
Valproate Neuroprotection Study
Determine whether chronic valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer’s disease who have not experienced agitation and psychosis in their illness.
Rage Inhibitor Study
The experimental drug in this study may block a critical pathway in Alzheimer’s disease that causes damage to the nerve cells in the brain.
Huperzine A (HU) Study
A multicenter, double-blind, placebo-controlled therapeutic trial to determine whether natural huperzine A improves cognitive function in Alzheimer’s disease.
T2 Protect AD Study
T2 is designed to determine if troriluzole can protect, slow down, or potentially improve memory and thinking problems that increase as Alzheimer’s disease progresses.
EXERT Study
The EXERT study is a national, 18-month long, clinical trial to test whether physical exercise can slow the progression of mild memory loss and/or mild cognitive impairment in older adults between the ages of 65-89.